Atamyo Therapeutics
Changing lives of neuromuscular patients with gene therapy.
Changing lives of neuromuscular patients with gene therapy.
Atamyo Therapeutics is a biotechnology startup with a focus on developing safe and effective gene therapies for neuromuscular diseases, aimed at changing the lives of patients affected by these conditions. The company, founded in 2020 in France, is a spin-off of the renowned gene therapy pioneer Genethon, leveraging expertise in AAV-based gene therapy and muscular dystrophies. Atamyo's key area of focus is on addressing limb-girdle muscular dystrophies (LGMD), with the aim of providing life-long efficient treatments. The company's name, derived from Celtic and Greek roots, symbolizes its commitment to perpetually improving the lives of those affected by neuromuscular diseases. With a strong foundation and support from Genethon, Atamyo Therapeutics has the potential to make a significant impact in the biotechnology and healthcare industries while offering promising opportunities for investment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 | EIC Accelerator | 15 Jul 2024 |
No recent news or press coverage available for Atamyo Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
